MRKR has been the subject of a number of other research reports. Zacks Investment Research cut shares of TapImmune from a buy rating to a hold rating in a research report on Wednesday, July 17th. Roth Capital started coverage on shares of TapImmune in a research report on Thursday, May 30th. They set a buy rating and a $10.00 target price for the company. Janney Montgomery Scott restated a buy rating on shares of TapImmune in a research report on Sunday, July 21st. Finally, Oppenheimer started coverage on shares of TapImmune in a research report on Wednesday, July 3rd. They set an outperform rating and a $15.00 target price for the company. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $10.21.
MRKR traded down $0.04 during midday trading on Thursday, reaching $4.26. 447,065 shares of the company’s stock were exchanged, compared to its average volume of 896,693. The company has a quick ratio of 19.73, a current ratio of 19.73 and a debt-to-equity ratio of 0.01. The firm has a market cap of $209.68 million, a PE ratio of -2.55 and a beta of 0.22. The company’s 50-day moving average price is $7.12. TapImmune has a 1-year low of $4.18 and a 1-year high of $10.60.
A hedge fund recently raised its stake in TapImmune stock. Riggs Asset Managment Co. Inc. increased its position in TapImmune Inc. (NASDAQ:MRKR) by 68.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,919 shares of the company’s stock after buying an additional 18,650 shares during the period. Riggs Asset Managment Co. Inc. owned about 0.10% of TapImmune worth $303,000 as of its most recent SEC filing. Institutional investors and hedge funds own 33.59% of the company’s stock.
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Featured Story: Cost of Goods Sold (COGS)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.